WellPATH-PREVENT: A Mobile Intervention for Middle-Aged and Older Adults Hospitalized for Suicidal Ideation or Attempt
Launched by WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY · Dec 20, 2021
Trial Information
Current as of November 14, 2025
Recruiting
Keywords
ClinConnect Summary
The WellPATH-PREVENT trial is studying a new mobile program designed to help middle-aged and older adults, aged 50 to 90, who have recently been hospitalized due to suicidal thoughts or attempts. The main goal is to see if this program can improve their ability to manage their emotions and reduce the risk of future suicide. This is particularly important for those who may struggle with feelings of sadness or hopelessness after leaving the hospital.
To be eligible for this trial, participants need to be between 50 and 90 years old and have experienced suicidal thoughts or attempts that required hospitalization. They should not have certain serious mental health conditions, like psychotic disorders or dementia. Participants can expect to use a mobile app that provides support and tools to help them cope better with their emotions. The trial is currently recruiting, and it aims to provide valuable insights into how technology can assist individuals during their recovery journey.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 50-90 years old
- • Diagnosis (based on a modified SCID-5 Clinical Trials Version to assess DSM-5 diagnoses): Any DSM-5 except: current diagnosis of Psychotic Disorder; diagnosis of Dementia
- • Recent hospitalization for suicidal ideation or suicide attempt; at hospital admission, Columbia Suicide Severity Rating Scale (CSSR-S) ≥ 2, "Non-specific Active Suicidal Thoughts."
- • We will also include patients on psychotropics and on after-care community psychotherapy.
- Exclusion Criteria:
- • Current diagnosis of Psychotic Disorders; Diagnosis of Dementia
- • Cognitive Impairment (MMSE ≤ 24)
- • Acute or severe medical illness (i.e., delirium; decompensated cardiac, liver or kidney failure; major surgery; stroke or myocardial infarction during the three months prior to entry
- • Aphasia, sensory problems, and/or inability to speak English.
About Weill Medical College Of Cornell University
Weill Medical College of Cornell University is a leading academic institution dedicated to advancing medical research and education. As a prominent sponsor of clinical trials, it focuses on innovative healthcare solutions and the development of new therapies across various medical disciplines. The institution is committed to fostering collaborative research efforts that enhance patient care and improve health outcomes. With a robust infrastructure and a team of experienced researchers and clinicians, Weill Cornell aims to translate scientific discoveries into practical applications, ensuring a strong emphasis on ethical standards and regulatory compliance throughout the clinical trial process.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
White Plains, New York, United States
New York, New York, United States
Patients applied
Trial Officials
Dimitris Kiosses, PhD
Principal Investigator
Weill Medical College of Cornell University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials